Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Daré Bioscience is a biotechnology business based in the US. Daré Bioscience stocks (DARE.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.34 – an increase of 9.71% over the previous week. Daré Bioscience employs 20 staff and has a market cap (total outstanding stock value) of $88.9 million.
Finder's Pick for
Beginners
Finder's Pick for
Free Trades
Finder's Pick for
Commodity Stocks
Finder's Pick for
US Stocks
| Latest market close | $1.13 |
|---|---|
| 52-week range | $0.92 - $2.51 |
| 50-day moving average | $1.38 |
| 200-day moving average | $1.60 |
| Wall St. target price | $7.20 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.63 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $1.13 from 2022-05-16
| 1 week (2022-05-07) | N/A |
|---|---|
| 1 month (2022-04-14) | N/A |
| 3 months (2022-02-14) | N/A |
| 6 months (2021-11-18) | -29.38% |
| 1 year (2021-05-18) | -17.52% |
|---|---|
| 2 years (2020-05-15) | 10.78% |
| 3 years (2019-05-17) | 26.82% |
| 5 years (2017-05-17) | 180.40% |
| Gross profit TTM | $-100,000 |
|---|---|
| Return on assets TTM | -77.08% |
| Return on equity TTM | -205.82% |
| Profit margin | 0% |
| Book value | $0.46 |
| Market capitalisation | $88.9 million |
TTM: trailing 12 months
We're not expecting Daré Bioscience to pay a dividend over the next 12 months.
Daré Bioscience's shares were split on a 1:10 basis on 19 July 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Daré Bioscience shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Daré Bioscience shares which in turn could have impacted Daré Bioscience's share price.
Over the last 12 months, Daré Bioscience's shares have ranged in value from as little as $0.92 up to $2.51. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Daré Bioscience's is 1.4233. This would suggest that Daré Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Daré Bioscience, Inc. , a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women.
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.
Read more…
Using our proprietary algorithm, we’ve found the best blue chip stocks on the TSX, NYSE and Nasdaq based on price, performance and more.
Read more…Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
Everything we know about the Actelis Networks IPO, plus information on how to buy in.
Everything we know about the ProFrac Holding Corp IPO, plus information on how to buy in.
Everything we know about the Wytec International IPO, plus information on how to buy in.
Here are some of the best stocks for inflation periods to reduce the negative impacts of inflation on your portfolio.
Choose from many account and investment types to invest in global markets, but expect to pay high commissions with HSBC InvestDirect, which doesn’t have an app.
Our Flahmingo review tells you how to buy fractional shares of some of your favourite US companies with as little as $1.
Steps to owning and managing EXPD stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PRU stock, with 24-hour and historical pricing before you buy.
